Table 5.

Val16Ala polymorphism and its effects on chemoprevention

RegressionNo regressionOR (95% CI; regression vs no regression)ProgressionNo progressionOR (95% CI; progression vs no progression)
n (%)n (%)n (%)n (%)
H. pylori treatment
    Val/Val109 (69.4)533 (73.3)1.00284 (72.3)358 (72.9)1.00
    Val/Ala+Ala/Ala48 (30.6)194 (26.7)1.06 (0.71-1.58)*109 (27.7)133 (27.1)1.07 (0.79-1.45)*
Garlic supplementation
    Val/Val170 (71.4)851 (74.8)1.00429 (74.0)592 (74.5)1.00
    Val/Ala+Ala/Ala68 (28.6)286 (25.2)1.13 (0.81-1.56)151 (26.0)203 (25.5)1.07 (0.83-1.38)
Vitamin supplementation
    Val/Val147 (69.0)863 (74.1)1.00431 (75.1)579 (72.0)1.00
    Val/Ala+Ala/Ala66 (31.0)302 (25.9)1.28 (0.92-1.07)143 (24.5)225 (28.0)0.83 (0.64-1.06)
  • *Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, garlic supplementation, and vitamin supplementation.

  • Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, H. pylori treatment, and vitamin supplementation.

  • Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, H. pylori treatment, and garlic supplementation.